
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Adel Signs $1.04B Global License Agreement with Sanofi for ADEL-Y01 Alzheimer's Therapy
Details : Through the licensing deal for ADEL-Y01, an unconjugated antibody targeting acK280, the agreement aims to advance Alzheimer's Disease research.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $80.0 million
December 16, 2025
